Clinical Trial Search

Primary: Number of Participants Reporting Each Category of Tolerance Assessed by the Tolerance Survey — 96; 31; 1; 121 number of participants

Primary: Percentage of Participants With Histological Clearance of Barrett's Metaplasia — 100; 20; 78; 82 Percent of Participants

Primary: Reversal of Oxidative DNA Damage as Assessed by Changes in 8-hydroxy-2' -Deoxyguanosine (8OHdG) Immunostaining — 1.62 % of strongly/moderately stained nuclei — p=0.54

Primary: Cytosponge Acceptability by Number of Participants — 46; 81; 2; 6 Participants

Primary: Percentage of Patients With Successful Eradication — 45.5; 38.1; 36.4; 19.04 percentage of participants

Primary: Percent Change From Baseline in Dysphagia Score in Patients With Eosinophilic Esophagitis (EE) — 69; 79 Percent Change

Primary: First Event of Death, Oesophageal Adenocarcinoma, High Grade Dysplasia — 127; 154; 174; 139 Participants — p=0.068

Primary: 7 Days Post-EGD Impact of Events Score (IES) — 1.42; 1.21; 0 units on a scale

Primary: Endoscopic Clearance Rate for Barrett's Esophagus-Percentage of Patients With no Endoscopically Visible Barrett's Esophagus at 1 Year Follow-up — 62.1 percentage of…

Primary: Mean Ki67 Expression — 35.6; 307.8 cells/mm2

Primary: Diagnostic Yield for Neoplasia in High Risk Patients(Suspected Neoplasia) — 34; 17 percent yield for neoplasia — p=0.01

Primary: Number of Barrett's Esophagus (BE) Participants With a Composite Outcome of "Optimally Treated" — 16; 16 participants

Primary: Change in Mean Tissue Prostaglandin E2 (PGE2) Concentration as Determined From Barrett's Research Mucosal Biopsy Samples — -67.6; -123.9; -174.9 pg/mL — p=0.0955

Primary: Number of Subjects That Would Have This Procedure Again — 19; 16 Participants

Primary: Change in Ki67 Biomarker Expression — 1539; 1556; 1575; 1864 cells/mm^2